Compass Pathways (NASDAQ:CMPS) Stock Rating Upgraded by Wall Street Zen

Compass Pathways (NASDAQ:CMPS) was upgraded by research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued on Sunday, Wall Street Zen reports.

CMPS has been the subject of a number of other research reports. Royal Bank Of Canada reissued an “outperform” rating on shares of Compass Pathways in a research report on Wednesday, November 4th. Oppenheimer reiterated an “outperform” rating and issued a $20.00 price objective on shares of Compass Pathways in a research note on Tuesday, November 3rd. Morgan Stanley lifted their price objective on shares of Compass Pathways from $17.00 to $18.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Jefferies Financial Group reissued a “buy” rating on shares of Compass Pathways in a report on Wednesday, September 9th. Finally, Wells Fargo & Company decreased their target price on shares of Compass Pathways from $13.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $23.14.

Compass Pathways Price Performance

Shares of NASDAQ CMPS opened at $9.18 on Friday. The firm has a market cap of $1.27 billion, a P/E ratio of -2.63 and a beta of 2.43. The business’s 50 day moving average is $12.22 and its 200-day moving average is $10.42. The company has a current ratio of 1.50, a quick ratio of 1.30 and a debt-to-equity ratio of 0.35. Compass Pathways has a 1-year low of $4.88 and a 1-year high of $15.87.

Compass Pathways (NASDAQ:CMPS) last released its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.08. Equities research analysts predict that Compass Pathways will post -0.83 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. ACT Capital Partners L.P. bought a new stake in Compass Pathways during the 3rd quarter worth approximately $567,000. Lisanti Capital Growth LLC acquired a new position in shares of Compass Pathways during the third quarter worth $2,468,000. Candriam S.C.A. lifted its holdings in shares of Compass Pathways by 18.6% during the third quarter. Candriam S.C.A. now owns 1,510,695 shares of the company’s stock worth $18,862,000 after purchasing an additional 236,417 shares during the period. Alps Advisors Inc. lifted its holdings in shares of Compass Pathways by 34.4% during the third quarter. Alps Advisors Inc. now owns 183,458 shares of the company’s stock worth $2,282,000 after purchasing an additional 46,996 shares during the period. Finally, CenterBook Partners LP grew its stake in shares of Compass Pathways by 454.1% in the third quarter. CenterBook Partners LP now owns 695,943 shares of the company’s stock worth $8,658,000 after purchasing an additional 570,349 shares during the last quarter. Institutional investors and hedge funds own 46.19% of the company’s stock.

Compass Pathways News Roundup

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: Compass Pathways completed its New Drug Application (NDA) submission for COMP360 psilocybin to treat treatment-resistant depression. The milestone brings the drug closer to regulatory review and is the main apparent catalyst for the stock’s rise. Company announcement
• Positive Sentiment: A Jefferies analyst said U.S. approval could come by early 2027, offering investors a potential timeline for the next major catalyst. Jefferies approval outlook
• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating, signaling continued analyst support. HC Wainwright rating
• Neutral Sentiment: The NDA submission is an important step, but the treatment remains investigational; the FDA’s review and any eventual decision are still ahead. NDA submission report
• Negative Sentiment: Wall Street Zen downgraded Compass Pathways to “Sell,” providing a counterpoint to the positive regulatory news and other analyst support. Wall Street Zen downgrade

Compass Pathways Company Profile

Compass Pathways plc is a biotechnology company developing treatments for mental health conditions. Founded in 2016 by George Goldsmith and Ekaterina Malievskaia, the company is focused on advancing psychedelic-based therapies through clinical research.

Its lead investigational product, COMP360, is a synthetic formulation of psilocybin being studied alongside psychological support. Compass is evaluating COMP360 primarily as a potential treatment for treatment-resistant depression and has also explored its use for other mental health conditions, including post-traumatic stress disorder.

Compass Pathways is headquartered in the United Kingdom and conducts clinical development internationally, including in the United States and Europe.